Summary
Global Peanut Allergy marketplace (8 major pharmaceutical markets - US, France, Germany, Italy, Spain, UK, Canada, and Australia) is to experience intense growth during the forecast period. It is forecasted that the Peanut Allergy market would grow over 1,700-fold between 2017 and 2027. This incredible growth stems from the projected entry of four new peanut immunotherapy products into a previously empty marketplace. These new therapies include three oral immunotherapy (OIT) products-Aimmune Therapeutics’ AR-101, Prota Therapeutics’ PPOIT, and Camallergy’s CA-002-and one epicutaneous immunotherapy product-DBV Technologies’ Viaskin Peanut.
Peanut allergy has prevalence of 1-2.5% in developed nations and a low rate of remission-only around 20% in children. Though the specific etiology of peanut allergy is unclear, it is likely due to the interaction of genetic predisposition with environmental factors. Currently the only available strategy for managing peanut allergy long-term is avoidance and the treatment of acute reactions with injectable epinephrine. Some physicians have begun to offer their patients an investigational treatment known as experimental peanut oral immunotherapy. Though these grassroots efforts can be effective in desensitizing patients to peanut, they lack standardization and regulatory agency approval, thus making it difficult to ensure the safety of the treatment. With a complete absence of approved therapies available, peanut allergy is an indication with extremely high unmet need.
Aimmune’s AR-101, is expected to be the market leader among the four peanut immunotherapy products released during the forecast, period, capturing over 67% of the peanut allergy market in 2027, worth an estimated $3.0B. Second in sales is DBV Technologies’ Viaskin Peanut, which is projected to capture 32% of the peanut allergy market in 2027, totaling nearly $1.4B in sales. Finally, sales for Prota Therapeutics’ and Camallergy’s products, PPOIT and CA-002, together are only expected to total 1%. This estimate is based on the Author’s assumption that within the forecast period these therapies will each only be released in one geography-Australia and the 5EU respectively.
Growing at a compound annual growth rate (CAGR) of 111% over the 10-year forecast period, in 2027 Peanut Allergy drug sales are projected to reach over $4.5 billion. The majority of sales (88%) will come from the US. This is mainly due to the US having a large population of potential patients (estimated 3,000,000 probable diagnosed prevalent cases), an elevated expected price tag for new therapies (nearly 5-7 times that of the other geographies), and a higher expected treatment rate (based on good accessibility to allergy specialists).
The report, "Peanut Allergy: Opportunity Analysis and Forecasts to 2027", analyzes the peanut allergy treatment landscape and provides detailed insights into the market dynamics of this rapidly developing space. Analysis includes the evaluation of the clinical and commercial profiles of four late-stage pipeline candidates as well as their sales forecasts between 2017 and 2027.
The report specifically -
- Assess the current competitive landscape for peanut allergy and its evolution over the forecast period (2017-2027)
- Evaluate the significance of late-stage pipeline products entering the peanut allergy market and determine how these products will impact the future treatment landscape
- Highlight the critical unmet needs within the peanut allergy market
- Identify opportunities for growth and innovation in the peanut allergy market
Scope
- Overview of peanut allergy including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized peanut allergy therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the peanut allergy therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global peanut allergy therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global peanut allergy therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global peanut allergy therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global peanut allergy therapeutics market from 2017-2027.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1 Table of Contents
2 Peanut Allergy: Executive Summary
2.1 Intense Growth Expected for Peanut Allergy Market Following Launch of First-in-Class Targeted Therapies
2.2 The Peanut Allergy Market is Currently Dominated by Small Biotech and Start-Up Companies Using Immunotherapies to Desensitize Patients to Peanut
2.3 Vast Unmet Needs Exist in the Peanut Allergy Market
2.4 Abundant Opportunities Remain for New Entrants to Improve Upon and Transform Therapeutic Options for Peanut Allergy
2.5 Launches of Novel Pipeline Products Will Revolutionize the Peanut Allergy Treatment Landscape and Generate Significant Sales
2.6 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Symptoms
4.3 Prognosis and Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for Peanut Allergy (2017-2027)
5.5.1 Probable Diagnosed Prevalent Cases of Peanut Allergy
5.5.2 Age-Specific Probable Diagnosed Prevalent Cases of Peanut Allergy
5.5.3 Sex-Specific Diagnosed Prevalent Cases of Peanut Allergy
5.5.4 Probable Diagnosed Prevalent Cases of Peanut Allergy with Comorbid Condition
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis
6 Current Treatment Options
6.1 Overview
6.2 Diagnosis
6.3 Treatment
6.3.1 Guidelines
6.3.2 Avoidance and Prevention
6.3.3 Acute Reactions
6.3.4 Peanut Desensitization Using Experimental Oral Immunotherapy
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Therapies Promoting Permanent Tolerance to Peanut
7.3 Biomarkers to Improve Diagnostic Sensitivity and Better Evaluate Patient Responses to Treatment
7.3.1 Improved Diagnostic Sensitivity
7.3.2 Biomarkers to Better Evaluate Patient Responses to Immunotherapy Treatment
7.4 Strategies to Minimize Side Effects in Immunotherapy Protocols
7.5 Strategies to Ensure Long-Term Compliance in Immunotherapy Protocols
7.6 Increased Access to Allergy Specialists
7.7 Enhanced Educational and Allergy Management Resources for a Broad Range of Audiences
8 R&D Strategies
8.1 Overview
8.1.1 Peanut Immunotherapies
8.1.2 Immuno-modulating Biologics Targeting Multiple Allergic Diseases
8.2 Clinical Trials Design
8.2.1 Current Clinical Trial Design
8.2.2 Biomarkers: Limitations and Future Outlook
8.2.3 Trial Design for Real-World Applicability
9 Pipeline Assessment
9.1 Overview
9.2 Innovative Early-Stage Approaches
9.3 Other Drugs in Development
10 Pipeline Valuation Analysis
10.1 Clinical Benchmark of Key Pipeline Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
10.4.1 US
10.4.2 5EU
10.4.3 Canada
10.4.4 Australia
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.3.1 Forecasting Methodology
11.3.2 Diagnosed Patients
11.3.3 Drug Treated Population for Peanut Allergy
11.3.4 Drugs Included in Each Therapeutic Class
11.3.5 Launch and Patent Expiry Dates
11.3.6 General Pricing Assumptions
11.3.7 Individual Drug Assumptions
11.3.8 Pricing of Pipeline Agents
11.4 Primary Research - KOLs Interviewed for This Report
11.4.1 KOLs
11.4.2 Payers
11.4.3 Community Allergists
11.5 Primary Research - Prescriber Survey
11.6 About the Authors
11.6.1 Analyst
11.6.2 Therapy Area Director
11.6.3 Epidemiologist
11.6.4 Epidemiology Reviewers
11.6.5 Global Director of Therapy Analysis and Epidemiology
11.6.6 Global Head and EVP of Healthcare Operations and Strategy
11.7 About
11.8 Contact Us
11.9 Disclaimer
1.1 List of Tables
Table 1: Peanut Allergy: Key Metrics in the 8MM, 2017-2
Table 2: Symptoms of Peanut-Induced Allergic Reactions
Table 3: Risk Factors and Comorbidities for Peanut Allergy
Table 4: SPT and sIgE Cutoffs for Peanut Allergy Diagnosis
Table 5: Popular Guidelines Available for Peanut Allergy, 2
Table 6: Clinical Criteria for Diagnosing Anaphylaxis
Table 7: Pharmacologic Management of Anaphylaxis
Table 8: Comparative Assessment of Peanut Immunotherapy Strategies, 2
Table 9: Clinical Trial Design for Key Immunotherapy Pipeline Agents in Late-stage Development, 2
Table 10: Comparison of Therapeutic Classes in Late-stage Development for Peanut Allergy
Table 11: Innovative Early-Stage Approaches for Peanut Allergy, 2
Table 12: Other Drugs in Development for Peanut Allergy, 2
Table 13: Clinical Benchmark of Key Pipeline Drugs - Peanut Allergy, 2
Table 14: Commercial Benchmark of Key Pipeline Drugs - Peanut Allergy, 2
Table 15: Key Events Impacting Sales for Peanut Allergy, 2017-2
Table 16: Peanut Allergy Market - Global Drivers and Barriers, 2017-2
Table 17: Key Projected Launch Dates for Peanut Allergy, 2017-2027
Table 18: Key Projected Patent Expiry Dates for Peanut Allergy, 2017-2027
Table 19: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: Global (8MM) Sales Forecast by Geography for Peanut Allergy in 2017 and 2
Figure 2: Competitive Assessment of Pipeline Drugs Benchmarked Against the SOC, Experimental Peanut OIT, 2017-2
Figure 3: Hypersensitivity Reaction to Peanut Allergen and Therapeutic Targets
Figure 4: Sensitization to Peanut Allergen and Therapeutic Targets
Figure 5: 8MM, Age-Standardized Probable Diagnosed Prevalence of Peanut Allergy, All Ages, 2
Figure 6: 8MM, Sources Used and Not Used to Forecast the Probable Diagnosed Prevalent Cases of Peanut Allergy
Figure 7: 8MM, Sources Used to Forecast the Probable Diagnosed Prevalent Cases of Peanut Allergy with Comorbidity of Asthma and AD
Figure 8: 8MM, Sources Used to Forecast the Probable Diagnosed Prevalent Cases of Peanut Allergy with Concomitant Food Allergy and Other Nut Allergy
Figure 9: 8MM, Probable Diagnosed Prevalent Cases of Peanut Allergy, Men and Women, All Ages, 2
Figure 10: 8MM, Age-Specific Probable Diagnosed Prevalent Cases of Peanut Allergy, Men and Women, N, 2
Figure 11: 8MM, Sex-Specific Probable Diagnosed Prevalent Cases of Peanut Allergy, All Ages, N, 2
Figure 12: 8MM, Probable Diagnosed Prevalent Cases of Peanut Allergy with Comorbid Condition, Men and Women, All Ages, N, 2
Figure 13: Typical Diagnostic Schemes for Peanut Allergy
Figure 14: Typical Management Scheme for an Individual Diagnosed with Peanut Allergy
Figure 15: Addendum Guidelines for Peanut Allergy Prevention
Figure 16: Global (8MM) Use of Different Branded and Generic Epinephrine Auto-injector Devices, 2
Figure 17: Rates of Epinephrine Auto-injector Prescription to Peanut Allergy Patients in the 8MM, 2
Figure 18: Unmet Needs and Opportunities in Peanut Allergy, 2
Figure 19: Estimated Accessibility to Allergists Throughout the 8MM
Figure 20: Overview of the Development Pipeline in Peanut Allergy, 2
Figure 21: Key Phase II/III Trials for the Pipeline Agents that the Author Expects be Licensed for Peanut Allergy in the 8MM During the Forecast Period, 2
Figure 22:Competitive Assessment of the Pipeline Drugs Benchmarked Against the SOC, Experimental Peanut OIT, 2
Figure 23: Global (8MM) Sales Forecast for Peanut Allergy, 2017-2
Figure 24: Global (8MM) Sales Forecast by Geography for Peanut Allergy in 2017 and 2
Figure 25: Global (8MM) Sales Forecast by Therapy for Peanut Allergy in 2017 and 2
Figure 26: Global (8MM) Sales Forecast by Age for Viaskin Peanut and AR-101 in 2
Figure 27: Sales Forecast by Therapy for Peanut Allergy in the US in 2017 and 2
Figure 28: Sales Forecast by Therapy for Peanut Allergy in the 5EU in 2017 and 2
Figure 29: Sales Forecast by Therapy for Peanut Allergy in Canada in 2017 and 2
Figure 30: Sales Forecast by Therapy for Peanut Allergy in Australia in 2017 and 2027
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aimmune Therapeutics
- DBV Technologies
- Prota Therapeutics
- Cambridge Allergy
- Sanofi
- Regeneron
- AnaptysBio
- Mylan
- ALK Abello
- Stallargenes Greer
- Astellas Pharma
- Immunomic Therapeutics
- HAL Allergy
- Aravax
- Immune Design
